Schering-Plough 1Q Revenues: $2.6 billion (+8%) 1Q Earnings: $350 million (earnings were $105 million in 1Q2005) Comments: The sales increase for the quarter was driven by Remicade, Nasonex, Temodar and Peg-Intron. Remicade sales were up 26% to $278 million, Temodar sales grew 25% to $163 million, Nasonex sales were up 25% to $229 million. Global sales of Peg-Intron were up 16% to $196 million in the quarter. R&D spending for the quarter totaled $481 million, up 25%....